Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Oncology·MeSH: Carcinoma, Non-Small-Cell Lung

Prevalence

75.0 / 100K

Incidence

47.0 / 100K/yr

5 drugs in development·4 companies·2 clinical trials

Drug Pipeline by Phase

Compare drugs

eftilagimod alfa vs tak-788

Frequently asked questions

How many drugs are in development for Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)?

BioSniper tracks 5 drugs in development for Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) across 4 companies.

How many clinical trials target Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)?

There are 2 clinical trials targeting Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) tracked by BioSniper.

What is the prevalence of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)?

The estimated prevalence of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) is approximately 75.0 per 100,000 population.

Deep-dive into Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) — Drugs in Development & Clinical Trials | BioSniper